Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) Research & Development: 2012-2024

Historic Research & Development for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$9.1 million.

  • BioLineRx's Research & Development fell 4.54% to -$2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$8.4 million, marking a year-over-year increase of 20.56%. This contributed to the annual value of -$9.1 million for FY2024, which is 26.92% up from last year.
  • According to the latest figures from FY2024, BioLineRx's Research & Development is -$9.1 million, which was up 26.92% from -$12.5 million recorded in FY2023.
  • BioLineRx's 5-year Research & Development high stood at -$9.1 million for FY2024, and its period low was -$19.5 million during FY2021.
  • In the last 3 years, BioLineRx's Research & Development had a median value of -$12.5 million in 2023 and averaged -$13.1 million.
  • Per our database at Business Quant, BioLineRx's Research & Development declined by 7.11% in 2021 and then rose by 28.99% in 2023.
  • Over the past 5 years, BioLineRx's Research & Development (Yearly) stood at -$18.2 million in 2020, then declined by 7.11% to -$19.5 million in 2021, then rose by 9.44% to -$17.6 million in 2022, then increased by 28.99% to -$12.5 million in 2023, then increased by 26.92% to -$9.1 million in 2024.